tetano
Editor, Senior Moderator
Antiviral Res
. 2023 Jun 25;105657.
doi: 10.1016/j.antiviral.2023.105657. Online ahead of print. The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza
Shengrui Mu[SUP] 1 [/SUP], Xiaohui Zou[SUP] 2 [/SUP], Yeming Wang[SUP] 3 [/SUP], Xiaoyan Deng[SUP] 4 [/SUP], Dan Cui[SUP] 5 [/SUP], Shuai Liu[SUP] 6 [/SUP], Bin Cao[SUP] 7 [/SUP]
Affiliations
Our previous study shows favipiravir and oseltamivir combination therapy may accelerate clinical recovery compared to oseltamivir monotherapy in severe influenza, but its effect on virological evolution and resistance mutation against oseltamivir is still unknown. In this study, we collected longitudinal respiratory samples from influenza patients who underwent combination therapy and applied them to next generation sequencing of the whole genome of the influenza A virus (IAV). We also included a cohort untreated with any antivirals to serve as the control. In total, 62 samples from 19 patients treated with combination therapy and 20 samples from 20 patients untreated were successfully sequenced. The nucleotide diversity in the whole genome of IAV in the combination group showed no difference compared to that in the control group (P > 0.05). Moreover, we observed 174 kinds of nonsynonymous nucleotide substitutions in patients with combination therapy, mostly in NA (n = 44) and HA (n = 43). Of them, the G→A transition was the dominant variant type (27%) and 46/174 (26%) was reported to have biological effects, such as increased pathogenicity and polymerase activity. Among the 29 mutations conferring reduction in oseltamivir sensitivity we investigated, H275Y was the only mutation detected in the 4 samples from 1 of 19 patients and demonstrated increasing frequency during the treatment. Mutations conferring favipiravir resistance were not observed. Our studies showed combination therapy of favipiravir and oseltamivir has little effect on virus nucleotide diversity, nor prevents the increase of oseltamivir-resistant variants.
Keywords: Combination therapy; Favipiravir; Influenza virus; Mutation; Whole genome sequencing.
. 2023 Jun 25;105657.
doi: 10.1016/j.antiviral.2023.105657. Online ahead of print. The combined effect of oseltamivir and favipiravir on influenza a virus evolution in patients hospitalized with severe influenza
Shengrui Mu[SUP] 1 [/SUP], Xiaohui Zou[SUP] 2 [/SUP], Yeming Wang[SUP] 3 [/SUP], Xiaoyan Deng[SUP] 4 [/SUP], Dan Cui[SUP] 5 [/SUP], Shuai Liu[SUP] 6 [/SUP], Bin Cao[SUP] 7 [/SUP]
Affiliations
- PMID: 37369282
- DOI: 10.1016/j.antiviral.2023.105657
Our previous study shows favipiravir and oseltamivir combination therapy may accelerate clinical recovery compared to oseltamivir monotherapy in severe influenza, but its effect on virological evolution and resistance mutation against oseltamivir is still unknown. In this study, we collected longitudinal respiratory samples from influenza patients who underwent combination therapy and applied them to next generation sequencing of the whole genome of the influenza A virus (IAV). We also included a cohort untreated with any antivirals to serve as the control. In total, 62 samples from 19 patients treated with combination therapy and 20 samples from 20 patients untreated were successfully sequenced. The nucleotide diversity in the whole genome of IAV in the combination group showed no difference compared to that in the control group (P > 0.05). Moreover, we observed 174 kinds of nonsynonymous nucleotide substitutions in patients with combination therapy, mostly in NA (n = 44) and HA (n = 43). Of them, the G→A transition was the dominant variant type (27%) and 46/174 (26%) was reported to have biological effects, such as increased pathogenicity and polymerase activity. Among the 29 mutations conferring reduction in oseltamivir sensitivity we investigated, H275Y was the only mutation detected in the 4 samples from 1 of 19 patients and demonstrated increasing frequency during the treatment. Mutations conferring favipiravir resistance were not observed. Our studies showed combination therapy of favipiravir and oseltamivir has little effect on virus nucleotide diversity, nor prevents the increase of oseltamivir-resistant variants.
Keywords: Combination therapy; Favipiravir; Influenza virus; Mutation; Whole genome sequencing.